Navigation Links
MDS Commences Arbitration against AECL over Cancelled MAPLE Project and Files $1.6 Billion Court Claim against AECL and the Government of Canada
Date:7/9/2008

TORONTO, July 9 /PRNewswire-FirstCall/ - MDS Inc. (TSX: MDS; NYSE: MDZ), a leading provider of products and services to the global life sciences markets, today announced that it has served Atomic Energy of Canada Limited (AECL) with notice of arbitration proceedings. MDS will be seeking an order to compel AECL to fulfill its contractual obligations under its 2006 interim and long-term supply agreement (ILTSA) and if not granted, seeking significant monetary damages. MDS has concurrently filed a court claim for $1.6 billion in damages against AECL, for negligence and breach of contract, and against the Government of Canada, for inducing breach of contract and for interference with economic relations.

"We have had to resort to taking these steps to protect the interests of patients, the nuclear medicine community, our shareholders and our customers," said Stephen P. DeFalco, President and CEO, MDS Inc. "We are disappointed that AECL and the Government decided to abandon the MAPLE project without establishing a clear plan for the long-term supply of critical medical isotopes."

MDS's primary objective through the legal proceedings is to have AECL honour its long standing commitment to replace the National Research Universal (NRU) reactor by bringing the MAPLE reactors into service, and provide a 40-year supply of medical isotopes, required by patients worldwide for serious medical needs.

In 1996, MDS entered into an agreement with AECL for the design, development and construction of two new nuclear reactors and a processing facility, known as the MAPLE project. The project was intended to replace AECL's NRU reactor, which produces approximately 50 per cent of the world's medical isotopes. AECL agreed to provide interim supply of medical isotopes from NRU until the MAPLE project was operational. The MAPLE project was to be completed by the year 2000 at a planned cost to MDS of $145 million.

By 2005, the project was not yet completed and
'/>"/>

SOURCE MDS Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Sun Pharma Commences All Cash Tender Offer to Purchase Taro Ordinary Shares for USD 7.75 Per Share
2. uKarma Corporation Commences International Distribution Agreement With Northern Response for its Xflowsion DVD Series
3. UltraShape(R) Commences Pivotal Study for First Non-Invasive Fat Reduction and Body Contouring Device Using Non-Thermal Selective Focused Ultrasound
4. China Sky One Medical, Inc. Commences Trading on the American Stock Exchange
5. Takeda Commences Cash Tender Offer for all Outstanding Shares of Millennium
6. SXC Health Solutions Corp. Commences Exchange Offer For Shares Of National Medical Health Card Systems, Inc.
7. Reckitt Benckiser Commences Cash Tender Offer for All Outstanding Shares of Adams Respiratory Therapeutics
8. Cytopia Commences Phase II Cancer Drug Study
9. Amarin Commences First Clinical Trial in Cardiovascular ProgramAmarin Commences First Clinical Trial in Cardiovascular Program
10. American Physicians Capital, Inc. Completes $15 Million Authorization and Commences $20 Million Authorization Under Stock Repurchase Program
11. Milestone Scientific Commences Declaratory Judgment Action With Respect to Its Single Tooth Anesthesia (STA(TM)) System and Compudent(TM) System

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/8/2009)...ation,s Job Creators ,, WASHINGTON, Nov. 8 /PRN...assage of the health care bill (H.R. 3962), Small ...il) president & CEO Karen Kerrigan issued the ...e voting for H.R. 3962 voted to burden our nation,...s and penalties. Even in the best of economic time...
(Date:11/8/2009)...uot;Preventing and Healing AIDS Through Our Inner ...IDS is a result of multiple, repeated and chronic ...tressor agents, which can be either chemical, phys... Oakland, CA (PRWEB) Novemb...ologists, physicians, chemists and other scientist...
(Date:11/8/2009)... Network (MHN) urges military veterans to learn ab... exposure to chemicals, atomic agents and soot or ... of those cancers that is two times more prevalent...currently smoke cigarettes. , ...’s Health Network (MHN) kicked-off their Vet...
(Date:11/8/2009)... is won," said Dr. Charmaine Yoest. ,, WASHING...f 240-194, the Stupak-Ellsworth-Pitts-Kaptur-Dahlk...n mandates and funding in HR 3962 passed on the Ho...President and CEO Dr. Charmaine Yoest said, "The p...life Americans across this country who have floode...
(Date:11/8/2009)...ire/ -- Pharmaceutical Research and Manufacturers ...on released the following statement regarding the ...pointed, but not surprised by today,s vote -- an u...ans as well as nearly half of the members of the U... bill. ,, "While well intentioned, the bill -- ...
Breaking Medicine News(10 mins):Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 2Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 3Health News:Veterans' Day Reminder from Men's Health Network: Pay Attention to Bladder Cancer Symptoms and Risk Factors 2Health News:Veterans' Day Reminder from Men's Health Network: Pay Attention to Bladder Cancer Symptoms and Risk Factors 3Health News:Americans United for Life Action Comments on Passage of Pro-Life Amendment: Bipartisan Pro-life Majority Reflects the Will of the American People 2Health News:PhRMA Statement on House Passage of Health Care Reform Bill 2Health News:PhRMA Statement on House Passage of Health Care Reform Bill 3
...ism and related advocacy groups are questioning th...providing a strategy for laying out// treatment re...Clement, in response has released a series of smal...and a Families for Early Autism Treatment advocacy...
...Technology, Jadavpur University, Kolkata and Depar...llege, Andhra Pradesh done a// study on Plumeria A...y was to evaluate the anti-inflammatory activity o.... Plumeria Acuminata belongs to the family o...
...loped at Singapore's National University Hospital ...said Saturday.// The hospital is conducting a ...ing treatment after the "optical biopsy" diagnosed...y cells. Pap smears, the usual method used to ...
...but to have a long life, one needs to make a consc...p bad habits.// A study tracked more than 5,8...e age was 54. The finding revealed that the chance...ad only a 22% chance of living till they were 85 y...
...dren may have sleep problems that regular physical... Research published in the November issue of ...t, inactive children tested positive for sleep-dis...ball and tag games, the number of children who tes...
... Board Hospital is experiencing a dearth of specia... manager, Sue Capenerhurst.// Mrs. Capenerhu...p with the shortfall in obstetricians till end-Dec...the crisis. The medical board is also in ...
Other Medicine News:Health News:Anti Inflammatory Evaluation Of Plumeria Acuminata Leaves 2Health News:Sleep Problems in Overweight Children Appear Fairly Common 2Health News:Sleep Problems in Overweight Children Appear Fairly Common 3
(Date:11/6/2009).... 6 SCOLR Pharma, Inc. (...the three and nine months ended September 30, 2009...ent and CEO, said, "We continue to advance discuss...rmulation. Several potential partners have committ...ternal resources as they evaluate the potential co...
(Date:11/6/2009)...PRNewswire/ -- Trius Therapeutics, Inc. announced ...n Form S-1 with the U.S. Securities and Exchange C...lic offering of shares of its common stock. All sh...g will be offered by the Company. ,, Credit Sui...nning manager, Piper Jaffray & Co. is acting a...
(Date:11/6/2009)...Newswire-FirstCall/ -- Caraco Pharmaceutical Labor...rolac tromethamine ophthalmic solution, 0.5% follo...ministration (FDA) for Sun Pharma,s Abbreviated Ne... ophthalmic solution on the first day following pa...rapeutically equivalent to Acular® Ophthalmic...
Breaking Medicine Technology:SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 2SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 3SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 4SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 5SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 6SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 7SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 8SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 9Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Ophthalmic Solution 2Siblings target of intervention program 50533 1Both good bad movie characters who smoke influence teens to do the same 50531 1Both good bad movie characters who smoke influence teens to do the same 50531 2Colorectal cancer 9090 1
...stems Incorporated,(Nasdaq: IMCL ) and Bristol-My...hat the U.S. Food and Drug Administration (FDA) ha... product labeling to include overall survival,data...bitor,(EGFR)-expressing metastatic colorectal canc...n- and oxaliplatin-based regimens. The approval o...
...edical Services,International Inc. (Pink Sheets: M...ts VScan Dengue Fever Kit is increasing. Dengue Fe...bbean in one of the worst,outbreaks in decades cau...s,of people and killing 200 people so far this yea...ted in the Americas and,with the upcoming rainy se...
Other Medicine Technology:Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 2Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 3Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 4Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 5Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 6Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 7Demand for VScan Dengue Fever Test Kits Increases 2
HA Pins
... Unite Device is the anterior alternative to the R...features the same 70% fenestrations as Ray TFC. Th...tions is paramount in the formation of new bone. A...oad sharing between the device and the spine.* In ...
...ta implant is the only approved radiolucent stand-...sion assessment with the proven reliability of the...s constructed of radiolucent, carbon-fiber reinfor...cted radiologic visualization, providing a new lev...
... HIV-1 RNA Assay (bDNA) delivers unmatched precisi...at you're providing physicians with viral load val...es at the low end and at other critical decision p...says. If you need more reasons to choose VERSANT H...
Medicine Products: